Diltiazem used as a tacrolimus-sparing agent for treatment of pediatric patients with refractory nephrotic syndrome: a case report and retrospective analysis

Eur J Clin Pharmacol. 2019 Apr;75(4):591-593. doi: 10.1007/s00228-018-2604-4. Epub 2018 Nov 27.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Child
  • Child, Preschool
  • Cytochrome P-450 CYP3A / genetics*
  • Cytochrome P-450 CYP3A / metabolism
  • Diltiazem / pharmacology
  • Diltiazem / therapeutic use*
  • Drug Interactions
  • Drug Resistance / genetics
  • Female
  • Glucocorticoids / pharmacology
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Nephrotic Syndrome / diagnosis
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / pathology
  • Retrospective Studies
  • Tacrolimus / pharmacology
  • Tacrolimus / therapeutic use*
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • CYP3A5 protein, human
  • Cytochrome P-450 CYP3A
  • Diltiazem
  • Tacrolimus